Healthpoint, DFB To Pay $48M To End FCA Drug Suit

Law360, New York (December 6, 2012, 4:03 PM EST) -- Healthpoint Ltd. and DFB Pharmaceuticals Inc. will pay $48 million as part of a settlement agreement that ended allegations that Healthpoint submitted false claims to Medicare and Medicaid for an unapproved prescription skin ointment, the U.S. Department of Justice said Thursday.

The DOJ said that in January 2011, it intervened in a False Claims Act case against Texas-based Healthpoint, a subsidiary of DFB, alleging the company launched Xenaderm, a prescription skin ointment used for treating nursing home patients' bedsores, without any approval from the U.S. Food...
To view the full article, register now.